Monitoring Parameters During Octreotide Infusion
During octreotide infusion, you must monitor blood glucose levels, cardiac rhythm/heart rate, thyroid function, and gastrointestinal symptoms, as these represent the most clinically significant adverse effects that can impact morbidity and mortality. 1
Critical Monitoring Parameters
Blood Glucose (Highest Priority)
- Monitor glucose tolerance and anti-diabetic treatment periodically throughout therapy 1
- Octreotide causes both hypoglycemia (3% of patients) and hyperglycemia (16% of patients) 1
- In Type 1 diabetics: Severe symptomatic hypoglycemia can occur; insulin requirements may need reduction 1
- In Type 2 diabetics and non-diabetics: May cause hyperglycemia due to decreased insulin levels 1
- One death has been reported from severe hyperglycemia and subsequent pneumonia following octreotide initiation 1
Cardiac Monitoring
- Monitor for bradycardia and conduction abnormalities 1
- Bradycardia (<50 bpm) occurs in 25% of patients 1
- Conduction abnormalities occur in 10% and arrhythmias in 9% 1
- ECG changes include: QT prolongation, axis shifts, early repolarization, low voltage, R/S transition changes 1
- Dose adjustments of beta-blockers and other bradycardia-inducing drugs may be necessary 1
- One case of worsening congestive heart failure has been reported 1
Thyroid Function
- Baseline and periodic assessment of TSH, total and/or free T4 is recommended during chronic therapy 1
- 12% develop biochemical hypothyroidism 1
- 8% develop goiter 1
- 4% require thyroid replacement therapy initiation 1
Gastrointestinal Symptoms
- Monitor for signs of pancreatitis - several cases reported 1
- Watch for gallstone symptoms: cholelithiasis, cholecystitis, cholangitis, pancreatitis 1
- Abdominal cramps, flatulence, and diarrhea are common but usually abate with continued treatment 2
- Do not routinely perform abdominal ultrasound unless symptomatic 2
Additional Monitoring Considerations
Drug Interactions Requiring Monitoring
- Cyclosporine: May decrease blood levels, risking transplant rejection 1
- Insulin and oral hypoglycemics: Require dose adjustments 1
- Beta-blockers and calcium channel blockers: May need dose adjustments 1
- Bromocriptine: Octreotide increases its bioavailability 1
- CYP3A4 substrates with narrow therapeutic index (e.g., quinidine): Use with caution and increased monitoring 1
Vitamin B12
- Monitor vitamin B12 levels during chronic therapy 1
- Depressed levels and abnormal Schilling's tests have been observed 1
Disease-Specific Monitoring
For acromegaly patients (if applicable):
- Monitor IGF-1 levels and clinical symptoms every 2-4 weeks during dose titration 3
- Once stable, monitor at longer intervals (3-6 months) 3
Common Pitfalls to Avoid
- Failing to anticipate glucose changes: Both hypo- and hyperglycemia can occur in the same patient population - don't assume one direction
- Overlooking cardiac effects in patients on beta-blockers: The combination significantly increases bradycardia risk
- Missing symptomatic gallstones: Only monitor with ultrasound if symptomatic, but educate patients on warning signs 2
- Inadequate monitoring in renal failure: Half-life increases in dialysis patients, requiring dosage adjustment 1